01
Read
Patient-level representationOrganize tumor sequencing, expression, and clinical context without flattening individual differences.
Start a conversation Computational mRNA oncology
Decode the tumor.
Design the message.
MendCipher Bio is building a computational platform to support the research and design of patient-specific mRNA therapeutics—connecting tumor data, constrained AI reasoning, and experimental learning.
Tumor-derived signal Designed mRNA candidate
01 Tumor profile→02 Target hypothesis→03 mRNA design→04 Experimental feedback
The premise
Cancer is not one disease.
Its biology changes person by person.
We are developing a workflow that treats this variation as the starting point: interpret the individual tumor, narrow the therapeutic design space, and generate candidates for disciplined experimental validation.
DESIGN PRINCIPLE / 001One patient.
One molecular context.
One molecular context.
The design loop
From evidence
to a testable design.
A closed-loop research architecture that connects computational intelligence with the reality check that matters: biology.
02
Reason
Traceable hypothesesUse domain-informed models and biological constraints to rank ideas, expose uncertainty, and support expert review.
03
Write
Candidate constructsTranslate selected hypotheses into testable mRNA designs shaped by biological and translational constraints.
04
Learn
Experimental feedbackBring laboratory results back into the system so the next design cycle begins with better evidence.
Our boundary
The model proposes.
Biology decides.
Language models can connect sequences, annotations, publications, and experimental records. They do not replace biological constraints, expert judgment, or reproducible validation.
Evidence provenanceExplicit uncertaintyHuman reviewExperimental validation
ABOUT / MENDCIPHER BIO
Founder-led. Research-stage.
Building deliberately.
Built for the one-of-one biology of cancer.
We work at the intersection of computational biology, mRNA engineering, and translational oncology—with a mission to make personalized therapeutic design more systematic, interpretable, and testable.
About the company